[go: up one dir, main page]

MX2018012176A - Anticuerpos anti-factor bb del complemento y usos de estos. - Google Patents

Anticuerpos anti-factor bb del complemento y usos de estos.

Info

Publication number
MX2018012176A
MX2018012176A MX2018012176A MX2018012176A MX2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A
Authority
MX
Mexico
Prior art keywords
antibodies
complement factor
complement
present disclosure
disclosure provides
Prior art date
Application number
MX2018012176A
Other languages
English (en)
Inventor
Panicker Sandip
Parry Graham
Sue Christopherson Karen
Sangyoung Byun Tony
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2018012176A publication Critical patent/MX2018012176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona anticuerpos anti-factor Bb del complemento y composiciones que comprenden los anticuerpos. Los anticuerpos anti-Bb son útiles para el tratamiento de trastornos mediados por el complemento. La presente descripción proporciona métodos para el tratamiento de trastornos mediados por el complemento.
MX2018012176A 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y usos de estos. MX2018012176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018012176A true MX2018012176A (es) 2019-02-07

Family

ID=60000646

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012176A MX2018012176A (es) 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y usos de estos.
MX2023007149A MX2023007149A (es) 2016-04-04 2018-10-04 Anticuerpos anti-factor bb del complemento y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007149A MX2023007149A (es) 2016-04-04 2018-10-04 Anticuerpos anti-factor bb del complemento y usos de estos.

Country Status (23)

Country Link
US (3) US10934347B2 (es)
EP (1) EP3452510A4 (es)
JP (3) JP6967528B2 (es)
KR (2) KR20240096672A (es)
CN (2) CN116790614A (es)
AU (2) AU2017246794B2 (es)
BR (1) BR112018070357A2 (es)
CA (1) CA3019332A1 (es)
CL (1) CL2018002810A1 (es)
CO (1) CO2018010827A2 (es)
CR (1) CR20180529A (es)
DO (1) DOP2018000219A (es)
EA (1) EA201892225A1 (es)
EC (1) ECSP18082302A (es)
IL (3) IL295288B2 (es)
MA (1) MA44878A (es)
MX (2) MX2018012176A (es)
MY (1) MY194603A (es)
PE (1) PE20190209A1 (es)
PH (1) PH12018502137A1 (es)
SG (1) SG11201808525UA (es)
TN (1) TN2018000341A1 (es)
WO (1) WO2017176651A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201906652T4 (tr) 2010-07-28 2019-05-21 Gliknik Inc Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
IL295288B2 (en) 2016-04-04 2024-08-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
CN110944672A (zh) * 2017-01-17 2020-03-31 得克萨斯A&M大学系统 用于改善载物分子向靶细胞的内溶酶体区室递送的内溶酶体靶向偶联物
TWI823868B (zh) * 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
CA3085945A1 (en) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
AU2020304415A1 (en) * 2019-06-27 2022-02-17 Verseau Therapeutics, Inc. Anti-CD53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP7631296B2 (ja) * 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド Ｈ因子増強性抗体及びその使用
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
CN115702165A (zh) 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
PL186073B1 (pl) 1993-10-25 2003-10-31 Canji Preparat farmaceutyczny, zwłaszcza do terapii genowej
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CN1160469C (zh) 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
WO1996019487A1 (en) 1994-12-22 1996-06-27 Nissan Chemical Industries, Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DK0939647T4 (da) 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
EP2500030B2 (en) 2005-11-04 2018-08-08 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
RU2456298C2 (ru) * 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Антитело против ilt17
CN101970002B (zh) * 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
JP2011503094A (ja) * 2007-11-08 2011-01-27 ジェネンテック， インコーポレイテッド 抗ｂ因子抗体およびそれらの使用
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
RU2011125366A (ru) 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
HK1199837A1 (en) 2011-10-27 2015-07-24 Nkt Therapeutics Inc. Humanized antibodies to inkt
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
US9243070B2 (en) * 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
PT2914291T (pt) * 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
JP6643244B2 (ja) 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
IL295288B2 (en) 2016-04-04 2024-08-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
CN115702165A (zh) 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途

Also Published As

Publication number Publication date
PH12018502137A1 (en) 2019-09-23
EP3452510A4 (en) 2020-01-15
MA44878A (fr) 2019-03-13
KR102673420B1 (ko) 2024-06-07
CA3019332A1 (en) 2017-10-12
CN109563158B (zh) 2022-08-09
JP2019513726A (ja) 2019-05-30
IL311675A (en) 2024-05-01
PE20190209A1 (es) 2019-02-07
JP7326393B2 (ja) 2023-08-15
KR20240096672A (ko) 2024-06-26
EA201892225A1 (ru) 2019-09-30
SG11201808525UA (en) 2018-10-30
TN2018000341A1 (en) 2020-06-15
US20210221877A1 (en) 2021-07-22
BR112018070357A2 (pt) 2019-01-29
WO2017176651A1 (en) 2017-10-12
DOP2018000219A (es) 2019-03-31
JP2023139289A (ja) 2023-10-03
NZ747018A (en) 2025-05-02
IL262010A (en) 2018-10-31
ECSP18082302A (es) 2019-01-31
IL295288B2 (en) 2024-08-01
CL2018002810A1 (es) 2019-03-15
AU2017246794A1 (en) 2018-10-25
IL295288B1 (en) 2024-04-01
KR20190003951A (ko) 2019-01-10
AU2024224000A1 (en) 2024-12-19
CN116790614A (zh) 2023-09-22
JP2021191789A (ja) 2021-12-16
IL295288A (en) 2022-10-01
EP3452510A1 (en) 2019-03-13
IL262010B (en) 2022-09-01
US20190153079A1 (en) 2019-05-23
MX2023007149A (es) 2023-06-28
US10934347B2 (en) 2021-03-02
US11851482B2 (en) 2023-12-26
CO2018010827A2 (es) 2018-11-22
AU2017246794B2 (en) 2024-07-04
CN109563158A (zh) 2019-04-02
MY194603A (en) 2022-12-06
US20240228599A1 (en) 2024-07-11
CR20180529A (es) 2019-03-21
JP6967528B2 (ja) 2021-11-17

Similar Documents

Publication Publication Date Title
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12019502283A1 (en) Anti-lag3 antibodies
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019007021A (es) Anticuerpos il-11ra.
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2019007020A (es) Anticuerpos il-11.
MX2022003272A (es) Anticuerpos anti-tau y metodos de uso.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
SG10201809668TA (en) Anti-her2 antibodies and immunoconjugates
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
NZ749279A (en) Compositions and methods related to engineered fc constructs
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
PH12020550023A1 (en) Compositions for treating stress-related disorders
PH12017501864A1 (en) Compositions and methods for treating autism
EP4480577A3 (en) Structured elements and methods of use